Post-treatment exercise programme improves survival for stage II/III colon cancer

Latest in bladder cancer from the second half of 2025

I-DXd shows strong brain metastasis responses in extensive-stage small cell lung cancer with manageable safety

Tarlatamab for SCLC: Subgroup analysis shows benefit regardless of previous chemo or anti-PD-(L)1 use

Tarlatamab improves symptoms and QoL over chemo in previously treated SCLC

Tarlatamab improves survival over chemo in 2L SCLC regardless of prior immunotherapy or chemo

Temab-A plus bevacizumab shows promising response rates in advanced colorectal cancer

ESMO 2025: Latest developments in endometrial cancer

ESMO 2025: Precision medicine in bladder cancer

Tarlatamab plus chemo-IO shows promising efficacy in extensive stage SCLC

ESMO 2025: Highlights and analysis

PRAME-targeted TCR therapy shows high response rates in metastatic uveal melanoma

Best practice in precision medicine for prostate cancer

ESMO 2025: Latest in EGFR mutant NSCLC

ctDNA test guides post-surgical immunotherapy for muscle-invasive bladder cancer

Neoadjuvant TAR-200 plus cetrelimab improves PCR in muscle-invasive bladder cancer

Visugromab plus nivolumab significantly increases pathologic response in muscle-invasive bladder cancer

ESMO 2025: Bladder cancer highlights

ctDNA-guided adjuvant atezolizumab improves OS in MIBC

ctDNA-guided adjuvant chemo de-escalation reduces toxicity with comparable outcomes in stage III colon cancer

ESMO 2025: Prostate highlights

ESMO 2025: Renal highlights

Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC

177Lu-PSMA-617 with androgen deprivation therapy plus ARPI improves PFS for mHSPC

Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors

177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity

Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant metastasis-free survival

Trastuzumab deruxtecan demonstrates advance in treatment for HER2-positive gastric cancer

IO102-IO103 cancer vaccine plus pembrolizumab demonstrates PFS benefit in advanced melanoma

Zanzalintinib plus atezolizumab improves survival in refractory mCRC

Durvalumab with BCG and maintenance therapy improves disease-free survival in high-risk NMIBC

Perioperative enfortumab vedotin plus pembro improves survival and pCR in cisplatin-ineligible MIBC

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC

Avelumab maintenance after reduced chemotherapy cycles improves QoL without sacrificing survival in aUC

Trastuzumab deruxtecan improves disease-free survival vs trastuzumab emtansine in high-risk HER2+ early breast cancer

Low-dose pembrolizumab plus neoadjuvant chemo option for TNBC in resource-constrained settings

Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC

Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer

Durvalumab combined with FLOT improves survival in resectable gastric and GEJ adenocarcinoma

Tarlatamab shows manageable safety profile with fewer toxicities than chemo in 2L SCLC

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection

Taletrectinib shows efficacy and tolerability in advanced ROS1+ NSCLC previously treated with entrectinib

Giredestrant plus everolimus new option in ER+, HER2– advanced breast cancer, post-CDK4/6 inhibitors

Circulating tumour DNA a useful marker in CRC treatment efficacy, but only alongside others